11-Desoxy-16-aryloxy-.omega.-tetranorprostaglandins
AssigneePfizer Inc.
InventorsJasjit S. Bindra, James F. Eggler, Michael R. Johnson, Thomas K. Schaaf
Life of this patent
Estimating the term…
Abstract
11-Desoxy-16-aryloxy-.omega.-tetranorprostaglandins are disclosed. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins but they exhibit a greater tissue specificity of action.
Claims12
The optically active compounds of the structure ##STR26## their optical antipodes and the racemates thereof wherein X and M are selected from the group consisting of keto, ##STR27## R' is selected from the group consisting of hydrogen, alkyl of from one to ten carbon atoms, aralkyl of from seven to nine carbon atoms, cycloalkyl of from three to eight carbon atoms, .alpha.-naphthyl, .beta.-naphthyl, phenyl and monosubstituted phenyl wherein the phenyl substituent is selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, lower alkyl, lower alkoxy and phenyl;
- and
- Ar is selected from the group consisting of phenyl, .alpha.-naphthyl, .beta.-naphthyl and monosubstituted phenyl wherein the substituent is selected from the group consisting of fluoro, chloro, bromo, lower alkyl, lower alkoxy, phenyl and trifluoromethyl.
A compound according to claim 8 wherein Ar is selected from the group consisting of phenyl, naphthyl and tolyl.
A compound according to claim 11 wherein Ar is phenyl and R' is hydrogen.
Dependencies are inferred from the claim text.